Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Following a fantastic event, Theolytics was announced the winner of the BioEscalator’s inaugural Pitch Finale, which was kindly supported by Santander Universities UK.

Following on from the success of our Pitch Battle in April, we sought to encourage the peer mentorship within our community. As the BioEscalator ecosystem currently comprises 13 high-growth companies in the early funding stages of seed to post series A, we were keen to utilise this wealth of knowledge and experience to support our companies in the process of raising series A, by matching our top start-ups with mentors from within our company pool. After 3 weeks of training and feedback on their business plans and investor slide decks, Theolytics, who are developing oncolytic viruses as therapeutics, Alchemab Therapeutics, who are utilising native antibodies and a novel platform to discover new therapeutics and Bioarchitech, who are developing novel oncolytic viral therapies, all gave excellent 6 minute pitches to our esteemed judging panel.

The full story is available on the BioEscalator website

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.